Skip to main content

A randomised, double-blind, placebo-controlled, dose-finding studyevaluating efficacy, safety, and tolerability of different oral doses of Bl 1819479 over atleast 24 weeks in patients with idiopathic pulmonary fibrosis (IPF)

Open
  • Protocol code: 1462-0004
  • EudraCT code: No aplica
  • Research group: Pneumology
  • Service: Pneumology
  • Principal investigator:  Ojanguren Arranz, Iñigo
  • Pathology: Malalties del sistema respiratori
  • Phase: Fase II